ES2290741T3 - Metodo de tratamiento de trastornos del tracto urinario inferior. - Google Patents

Metodo de tratamiento de trastornos del tracto urinario inferior. Download PDF

Info

Publication number
ES2290741T3
ES2290741T3 ES04758741T ES04758741T ES2290741T3 ES 2290741 T3 ES2290741 T3 ES 2290741T3 ES 04758741 T ES04758741 T ES 04758741T ES 04758741 T ES04758741 T ES 04758741T ES 2290741 T3 ES2290741 T3 ES 2290741T3
Authority
ES
Spain
Prior art keywords
medication
bladder
esters
amides
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04758741T
Other languages
English (en)
Spanish (es)
Inventor
Steven B. Landau
Cheryl L. Miller
Matthew O. Fraser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynogen Pharmaceuticals Inc
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2290741T3 publication Critical patent/ES2290741T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES04758741T 2003-04-04 2004-04-02 Metodo de tratamiento de trastornos del tracto urinario inferior. Expired - Lifetime ES2290741T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US46102203P 2003-04-04 2003-04-04
US461022P 2003-04-04
US49650203P 2003-08-20 2003-08-20
US496502P 2003-08-20
US53634104P 2004-01-13 2004-01-13
US536341P 2004-01-13

Publications (1)

Publication Number Publication Date
ES2290741T3 true ES2290741T3 (es) 2008-02-16

Family

ID=33162987

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04758741T Expired - Lifetime ES2290741T3 (es) 2003-04-04 2004-04-02 Metodo de tratamiento de trastornos del tracto urinario inferior.

Country Status (9)

Country Link
US (5) US6846823B2 (cg-RX-API-DMAC7.html)
EP (1) EP1539181B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006522144A (cg-RX-API-DMAC7.html)
AT (1) ATE365554T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004227945B2 (cg-RX-API-DMAC7.html)
CA (1) CA2519379A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004007225T2 (cg-RX-API-DMAC7.html)
ES (1) ES2290741T3 (cg-RX-API-DMAC7.html)
WO (1) WO2004089288A2 (cg-RX-API-DMAC7.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7085845B2 (en) * 2001-05-09 2006-08-01 Gene Fein Method, apparatus and computer program product for identifying a playing media file and tracking associated user preferences
CN100355419C (zh) * 2002-06-07 2007-12-19 安斯泰来制药有限公司 治疗膀胱过度活动的药物
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
CA2510292A1 (en) * 2002-12-20 2004-07-15 Dynogen Pharmaceuticals, Inc. Methods of treating non-painful bladder disorders using .alpha.2.delta. subunit calcium channel modulators
KR100742001B1 (ko) * 2003-03-21 2007-07-23 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
CA2519379A1 (en) * 2003-04-04 2004-10-21 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
US20060188554A1 (en) * 2003-08-04 2006-08-24 Katashi Nakashima Transdermal absorption preparation
EP1727527A1 (en) * 2004-03-19 2006-12-06 Solvay Pharmaceuticals GmbH Use of a 5-ht3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain
US7820690B2 (en) * 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
JP2008516909A (ja) * 2004-10-18 2008-05-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 前立腺及び下部泌尿生殖路の病気を治療するためのβ−3アゴニストの使用
WO2006066110A2 (en) * 2004-12-14 2006-06-22 The Johns Hopkins University Cav2 RELATED COMPOSITIONS AND METHODS
JP2008524332A (ja) 2004-12-20 2008-07-10 コレジウム ファーマシューティカル, インク. 睡眠傷害のための医薬組成物
KR20070121644A (ko) * 2005-01-14 2007-12-27 유리젠, 인코포레이티드 하부 요로 치료용 키트 및 개선된 조성물
WO2006093774A2 (en) * 2005-02-25 2006-09-08 Solvay Pharmaceuticals, Inc. Method of treatment of diarrhea-predominant ibs in a female subject receiving contraceptive therapy
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US20070093520A1 (en) * 2005-04-15 2007-04-26 Caras Steven D Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject
EP1906951A4 (en) * 2005-07-01 2009-05-27 Dynogen Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL HYPOMOTILITY AND RELEVANT DISEASES
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
FR2895259B1 (fr) * 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
US20070172508A1 (en) * 2006-01-26 2007-07-26 Paul Zupkas Transluminal drug delivery methods and devices
US20070172507A1 (en) * 2006-01-26 2007-07-26 Paul Zupkas Transluminal drug delivery methods and devices
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8642093B2 (en) 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US7975699B2 (en) * 2007-10-30 2011-07-12 The Invention Science Fund I, Llc Condoms configured to facilitate release of nitric oxide
EP1997807A1 (en) * 2007-05-28 2008-12-03 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
CN102058885B (zh) * 2006-12-22 2013-04-10 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
US20090274722A1 (en) * 2007-01-29 2009-11-05 Ligums John E Therapeutic Composition for the Treatment of BPH and ED
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
WO2008114220A2 (en) * 2007-03-19 2008-09-25 Insuline Medical Ltd. Device for drug delivery and associated connections thereto
EP2131900B1 (en) * 2007-03-19 2018-05-30 Insuline Medical Ltd. Drug delivery device
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
WO2009081262A1 (en) 2007-12-18 2009-07-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
CA2688542C (en) * 2007-05-30 2016-07-12 Michael J. Martin Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US20110171195A1 (en) * 2007-06-15 2011-07-14 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
US20110182970A1 (en) * 2007-10-30 2011-07-28 Hyde Roderick A Nitric oxide sensors and systems
US10080823B2 (en) * 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
SI2216021T1 (sl) 2007-11-02 2013-01-31 Astellas Pharma Inc. Farmacevtski sestavek za zdravljenje prekomerno aktivnega sečnega mehurja
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
RU2532893C2 (ru) 2008-11-07 2014-11-10 Инсьюлин Медикал Лтд. Устройство и способ доставки лекарственных средств
EP2364138A2 (en) * 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110000481A1 (en) * 2009-07-01 2011-01-06 Anand Gumaste Nebulizer for infants and respiratory compromised patients
US9180263B2 (en) * 2009-07-01 2015-11-10 Microdose Therapeutx, Inc. Laboratory animal pulmonary dosing device
CN102665807A (zh) 2010-01-05 2012-09-12 微剂量治疗技术公司 吸入设备和方法
US10238821B2 (en) 2016-10-11 2019-03-26 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
WO2020030777A1 (en) * 2018-08-10 2020-02-13 Grünenthal GmbH Composition for treating urinary frequency and/or urinary urgency

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046489A (en) 1958-11-28 1962-07-24 Elcor Inc Wide band direct coupled amplifier
US3161155A (en) 1961-02-04 1964-12-15 Orlandi Giorgio Food-dough cords spacing device
JPS60146891A (ja) * 1984-01-05 1985-08-02 Mitsubishi Chem Ind Ltd 〔2,3−d〕チエノピリミジン誘導体およびその塩
DE3422155A1 (de) 1984-06-14 1985-12-19 Alfred Teves Gmbh, 6000 Frankfurt Hydraulische servofahrzeugbremse
AU1295088A (en) 1987-01-30 1988-08-24 American Home Products Corporation Des-epidermal growth factor plasminogen activators
DE3885357T2 (de) 1987-06-29 1994-03-24 Duphar Int Res Anellierte Indolderivate.
US5225407A (en) 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
CA2044854A1 (en) * 1990-07-19 1992-01-20 Hong-I Chen Method for preventing or treating urinary incontinence
ZA921292B (en) * 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
WO1993000074A1 (en) 1991-06-26 1993-01-07 Sepracor, Inc. Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
JP2699794B2 (ja) 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔3,2−b〕ピリジン誘導体
JPH0616557A (ja) * 1992-12-21 1994-01-25 Mitsubishi Kasei Corp 脳機能障害改善剤
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
DK0855397T3 (da) 1995-07-28 2001-06-25 Dainippon Pharmaceutical Co (R)-5-brom-N-(ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridincarboxamid, fremgangsmåde til dets fremstilling og medicinsk præparat indeholdende denne forbindelse
AU702594B2 (en) 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
AU745361B2 (en) 1997-04-18 2002-03-21 Janssen Pharmaceutica N.V. Use of 5HT3 antagonists for promoting intestinal lavage
JPH10298078A (ja) 1997-05-06 1998-11-10 Mitsubishi Chem Corp 抗不安薬
DE19813661A1 (de) 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
DE19734444A1 (de) 1997-08-08 1999-02-11 Basf Ag 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung
FR2781671A1 (fr) 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
WO2000024716A1 (en) 1998-10-23 2000-05-04 Ajinomoto Co., Inc. Dihydropyridine derivatives and drug compositions containing the same
US6272553B2 (en) * 1998-11-20 2001-08-07 Sprint Communications Company, L.P. Multi-services communications device
WO2000048581A2 (en) 1999-02-18 2000-08-24 Novartis Ag Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
GB2355932B (en) * 1999-04-12 2004-01-07 Univ Madras A pharmaceutical formulation suitable for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
DE19929197A1 (de) 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
ATE305788T1 (de) 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US6846496B1 (en) * 1999-10-15 2005-01-25 Orion Corporation Treatment of osteoporosis
WO2001051496A1 (en) * 2000-01-14 2001-07-19 Rhodia, Inc. Crosslinking agents for textile finishing baths
WO2001062236A2 (en) 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
JP2002026134A (ja) * 2000-07-12 2002-01-25 Seiko Epson Corp 半導体集積回路の製造方法及びこの方法により製造した半導体集積回路
GB0112494D0 (en) 2001-05-22 2001-07-11 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
AU2003210610B2 (en) 2002-01-18 2007-11-29 Aryx Therapeutics 5-HT3 receptor antagonists and methods of use
GB0202265D0 (en) 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
PT1485078E (pt) 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
CN1668307A (zh) 2002-07-10 2005-09-14 阿瑞科诺沃治疗有限公司 治疗功能性肠紊乱的4-(2-氟苯基)-6-甲基-2-(1-哌嗪基)噻吩并[2,3-d]嘧啶
AU2003259373B2 (en) 2002-08-29 2006-03-09 Dynogen Pharmaceuticals, Inc. New therapeutic uses of (4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-D]pyrimidine
ES2285407T3 (es) * 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
KR20050111318A (ko) * 2003-01-13 2005-11-24 다이노젠 파마세우티컬스, 인코포레이티드 기능성 장 질환을 치료하는 방법
CA2519379A1 (en) * 2003-04-04 2004-10-21 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
US20050151367A1 (en) * 2003-12-18 2005-07-14 Packard Joy A. Fastener for a display page

Also Published As

Publication number Publication date
WO2004089288A3 (en) 2005-04-21
EP1539181A2 (en) 2005-06-15
EP1539181A4 (en) 2005-12-28
AU2004227945A1 (en) 2004-10-21
US7115606B2 (en) 2006-10-03
WO2004089288A2 (en) 2004-10-21
ATE365554T1 (de) 2007-07-15
CA2519379A1 (en) 2004-10-21
US20050026909A1 (en) 2005-02-03
US6846823B2 (en) 2005-01-25
US20050272719A1 (en) 2005-12-08
JP2006522144A (ja) 2006-09-28
US20050282799A1 (en) 2005-12-22
EP1539181B1 (en) 2007-06-27
DE602004007225T2 (de) 2008-03-06
DE602004007225D1 (de) 2007-08-09
US20040209869A1 (en) 2004-10-21
US20050020577A1 (en) 2005-01-27
AU2004227945B2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
US6846823B2 (en) Method of treating lower urinary tract disorders
ES2275229T3 (es) Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
US7459430B2 (en) Methods of using ziconotide to treat overactive bladder
US20040248979A1 (en) Method of treating lower urinary tract disorders
US20040209960A1 (en) Methods of treating lower urinary tract disorders using sodium channell modulators
US20060293309A1 (en) Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US20050282859A1 (en) Dual acting SNRI-NMDA antagonists for the treatment of genitourinary disorders
EP3251665A1 (en) Drug combinations and uses in treating a coughing condition
ES2288641T3 (es) Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
US7223754B2 (en) Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
EP1795196A2 (en) Method of treating lower urinary tract disorders
AU2007200317A1 (en) Method of treating lower urinary tract disorders
ZA200507879B (en) Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
ZA200505142B (en) Methods of treating non-painful bladder disorders using &2.d subunit calcium channel modulators